Apexigen Inc. (APGN)
0.39
0.04 (9.86%)
At close: Aug 22, 2023, 7:59 PM
9.86% (1D)
| Bid | n/a |
| Market Cap | 9.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.66M |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -0.2252046783625731 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 94,426 |
| Avg. Volume (20D) | 262,332 |
| Open | 0.36 |
| Previous Close | 0.35 |
| Day's Range | 0.36 - 0.40 |
| 52-Week Range | 0.33 - 8.28 |
| Beta | 3.62 |
About APGN
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation the...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 22, 2021
Employees 11
Stock Exchange NASDAQ
Ticker Symbol APGN
Website https://www.apexigen.com